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Abstract
Free or loosely chelated iron has tumor-promoting properties in vitro. Curcumin, a polyphenol 
derived from the food spice turmeric (Curcuma longa), is a potent antioxidant that binds iron. The 
primary aim of this study was to investigate whether curcuminoids prevent tumor-promoting 
effects of iron in T51B cells, a non-neoplastic rat liver epithelial cell line. Purified curcuminoids 
(curcumin) or a standardized turmeric extract similarly reduced oxidative stress and cytotoxicity 
associated with iron overload (IC50 values near 10 μM, P < 0.05). Inhibition of iron-induced tumor 
promotion (seen upon treatment with 200 μM ferric ammonium citrate ± curcumin/turmeric for 16 
wk in culture; subsequently assayed by soft agar colony formation) was nearly complete at 20 μM 
of total curcuminoids (P < 0.05), a concentration predicted to only partially chelate the added iron. 
Surprisingly, lower curcumin concentrations (10 μM) increased tumor promotion (P < 0.01). 
Curcuminoids delivered as a standardized turmeric extract were taken up better by cells, had a 
longer half-life, and appeared more effective in blocking tumor promotion (P < 0.01), suggesting 
enhanced curcuminoid delivery to cells in culture. The primary finding that curcuminoids can 
inhibit tumor promotion caused by iron in T51B cells is tempered by evidence for an underlying 
increase in neoplastic transformation at lower concentrations.
Introduction
Turmeric is the powdered rhizome (root) of the Asian plant Curcuma longa commonly used 
as a food spice and coloring agent. It also has a long history of medicinal uses generally 
ascribed to a high content of bioactive compounds including the polyphenolic iron-binding 
compound curcumin and related curcuminoids (1,2) (Fig. 1). Curcumin has been widely 
studied in recent years, with a number of documented anti-inflammatory and anticancer 
properties. Although the molecular effects of curcumin in vitro and in vivo are consistent 
with cancer prevention activity in the liver, dietary curcumin has not consistently reduced the 
incidence of primary liver cancer in several rodent models (3,4).
Iron is an essential metal but can be cytotoxic at high levels, where redox cycling of free or 
loosely chelated iron causes oxidative stress in cells (5). The liver is the main storage organ 
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for excess body iron, making it particularly vulnerable to toxicities of iron overload. 
Accumulation of iron in the livers of hemochromatosis patients can lead to liver fibrosis, 
cirrhosis, and hepatocellular carcinoma. The incidence of primary liver cancer is higher in 
hemochromatosis than in other causes of chronic liver disease and cirrhosis (6–8). Possible 
carcinogenic effects of iron include direct action as a mutagen (9) as well as tumor-
promoting effects (10). We found previously that iron acts as a tumor promoter but is not by 
itself carcinogenic in the T51B rat liver cell carcinogenesis model (11).
Repeated cycles of hepatotoxicity and regrowth/regeneration are a common theme of agents 
that act as liver tumor promoters (12). Because of this, any agent that binds iron tightly or 
otherwise reduces its cytotoxic effects should prevent tumor promotion. In T51B cells, 
tumor promotion by iron was blocked by the high-affinity iron chelator deferoxamine (11). 
Curcumin, which can bind iron with micromolar affinity and prevent iron toxicity (13–15), 
may have similar effects. The aim of this work was to test the in vitro anticancer effects of 
both a defined mixture of pure curcuminoids and a standardized turmeric extract. We 
evaluated the concentration dependence of these two preparations to inhibit cytotoxicity and 
tumor promotion associated with iron overload in T51B liver epithelial cells.
Methods
Materials
N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), ferric ammonium citrate (FAC), and 8-
hydroxyquinoline (8HQ) were obtained from Sigma-Aldrich (St. Louis, MO). Newborn calf 
serum was from Atlanta Biologicals (Norcross, GA), and other cell culture reagents were 
from GIBCO/Invitrogen (Carlsbad, CA). Turmeric and purified curcuminoids (C3 
complex®, a defined mixture of curcumin (diferuloylmethane), demethoxycurcumin, and 
bisdemethoxycurcumin) were donated by Sabinsa Corporation (Piscataway, NJ). One lot of 
purified curcuminoids (C3 complex®) and two lots of turmeric were used for this study. The 
curcuminoid concentrations of these preparations are listed in Table 1. Low-temperature 
melting point agarose was obtained from Lonza (Walkersville, MD).
Test Product Quality
Turmeric and purified curcuminoids (C3 complex®) were evaluated and stored in 
accordance with the manufacturer’s recommendations. These test products met quality 
standards expected of substances intended for human consumption (Sabinsa Corporation), as 
required by the Product Integrity Working Group of the National Advisory Council for 
Complementary and Alternative Medicine, a primary sponsor of this study. Quality 
standards included specifications of the World Health Organization for Rhizoma Curcumae 
Longae as to identity, product purity and chemical/biological contamination (16). Purified 
curcuminoids were dissolved in dimethylformamide to a final concentration of 50 mM and 
stored at −20°C. Turmeric powder (containing not less than 3.0% w/w total curcuminoids) 
was extracted with 1.6 ml of dimethylformamide/g for 30 min at room temperature, and 
particulates were removed by 0.45 μm filtration. Extracts were adjusted to a standardized 
concentration of 50 mM curcuminoids (quantified by absorbance at 425 nm relative to a 
defined curcuminoid standard) and stored at −20°C. Monitoring of the turmeric extracts and 
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purified curcuminoid stock solutions showed no change in curcuminoid concentrations over 
a period of more than 1 yr. Where indicated the curcuminoids or turmeric extract was added 
along with iron directly to the culture media; control cultures contained an equal amount of 
dimethylformamide (≤0.1% by volume) and/or other solvents as appropriate. The 
curcuminoid composition of the test products was determined by reverse-phase high 
performance liquid chromatography (HPLC) using an Inertsil ODS-3 column (Agilent, 
Santa Clara, CA), with an isocratic mobile phase of tetrahydrofuran: 0.1% citric acid 
(40:60), as detected by absorbance at 425 nm. Integration of peak areas gave the relative 
amounts of curcuminoids listed in Table 1.
Cell culture and biological assays
T51B cells are a non-neoplastic rat liver epithelial cell line maintained as described 
previously (11). These well-characterized cells have been used previously by us and others 
to document carcinogenesis and tumor promotion activity in vitro (17–19). They display a 
normal phenotype of density-inhibited and anchorage-dependent proliferation, but can be 
transformed to grow in soft agar (an accepted measure of neoplastic transformation) by 
treatment with carcinogens and tumor promoters (20). T51B cells have characteristics of 
liver oval cells; we believe that their transformation models hepatocellular carcinoma that 
originates from this hepatocyte precursor (21).
In general, experimental treatments were started while the cells were actively proliferating 
(one day after plating) except as noted (confluent T51B cells are largely quiescent). Chronic 
iron overload was induced by adding iron (as FAC) directly to the culture media for the 
prescribed time. Acute iron overload was induced using the lipophilic iron chelator 8HQ to 
rapidly deliver iron to intracellular compartments (15). Lipid peroxidation was measured in 
confluent cells by thiobarbituric reactive substances (TBARS) assay using a kit from 
Cayman Chemical (Ann Arbor, MI), and the results were expressed relative to control cells 
as malondialdehyde (MDA) equivalents. To assess cell viability, treated cells were incubated 
in 0.3 μg/ml methylthiazolyldiphenyl-tetrazolium bromide (MTT), and the formazan 
mitochondrial reduction product was dissolved in DMSO and measured by absorbance at 
540 nm (15).
Neoplastic transformation was assessed by determining colony formation in soft agar as 
described (11). The transformation protocol specified a single 24 h treatment with 0.5 μg/ml 
MNNG followed by continuous culture with 200 μM FAC with or without added 
curcuminoids (Supplemental Table 1). Previous work optimized these conditions for iron-
related carcinogenesis in the T51B cell model (11). Although this iron concentration is 
higher than that normally encountered in human iron overload (~10–20 μM serum iron 
citrate levels (22)), the form of iron is the same. Higher concentrations were justified by the 
need to observe neoplastic transformation at a reasonable rate within a reasonable time 
(compared to human liver cancer that generally requires 20–30 yr to appear in the setting of 
iron overload). In general, the media was renewed every 3–4 days, and the cells were split 
every 14 days. For splitting, 200,000 cells were replated into a new P60 dish, and treatments 
resumed 1 day later. At prescribed times (nominally 16 wk), cell aliquots (25,000 cells per 
P60 soft agar plate) were plated in quadruplicate soft agar dishes, grown without treatment 
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for 3 wk, stained with 0.5 mg/ml iodonitrotetrazolium violet, and counted. Colonies larger 
than 0.17 mm in diameter (approximately 100 cells) were scored as positive.
Tumor promotion results are presented from three experiments that differed slightly in 
curcuminoid treatments. The conditions and number of soft agar dishes evaluated in each 
experiment are as follows (Supplemental Table 2): Experiment 1 included control (n = 8), 
0.5 μg/ml MNNG + 200 μM FAC (n = 32), MNNG + FAC + 50 μM curcuminoids (n = 28), 
and MNNG + FAC + 30 μM turmeric (n = 16). MNNG was given once, while curcuminoids/
turmeric and FAC were added the next day and renewed with fresh media approximately 
twice a week thereafter. Evaluation of 50 μM turmeric was discontinued during the 
experiment due to poor cell growth. Experiment 2 included control (n = 8), 0.5 μg/ml 
MNNG + 200 μM FAC (n = 12), MNNG + FAC + 10 μM (n = 8), MNNG +FAC + 20 μM 
curcuminoids (n = 8), MNNG + FAC + 30 μM curcuminoids (n = 8), MNNG + FAC + 5 μM 
turmeric (n = 8), MNNG + FAC + 10 μM turmeric (n = 8), and MNNG + FAC + 20 μM 
turmeric (n = 8). MNNG was given once, while curcuminoids/turmeric and FAC were 
renewed every 3–4 days thereafter. Experiment 3 included control (n = 8), 0.5 μg/ml MNNG 
+ 200 μM FAC (n = 40), MNNG + FAC + 5 μM curcuminoids (n = 8), MNNG + FAC + 10 
μM curcuminoids (n = 8), MNNG + FAC + 20 μM curcuminoids (n = 8), MNNG + FAC 
+ 30 μM curcuminoids (n = 8), MNNG + FAC + 5 μM turmeric (n = 8), MNNG + FAC + 10 
μM turmeric (n = 8), and MNNG + FAC + 20 μM turmeric (n = 8). MNNG was given once, 
while curcuminoids/turmeric and FAC were renewed every 2–3 days thereafter. Results from 
these separate experiments were grouped according to treatment conditions as specified.
Curcuminoid uptake in cells was determined under normal adherent monolayer culture 
conditions at specified times. Cells were placed on ice and then rinsed twice with 0.1% 
bovine serum albumin in phosphate-buffered solution (PBS), twice with PBS, and scraped in 
reagent ethanol. The total curcuminoid concentrations in the ethanolic extracts were 
measured by absorbance at 425 nm and expressed as absorbance units. Relative curcuminoid 
composition was assessed by HPLC as described above.
Statistics
To determine the significance of differences between groups (primarily cells treated with 
curcuminoids/turmeric vs. cells not given these test products), the data were evaluated using 
a 2-tailed unpaired t-test for samples with unequal variance, and significance was noted at P 
< 0.05 (*), P < 0.01 (**), and P < 0.001 (***). Normalized values (expressed relative to 
control cells) were used to compile data from the TBARS experiments. A paired t-test was 
used when testing significance relative to the normalizing group itself.
Results
Curcuminoids protect against the cytotoxic effects of acute iron overload
Redox cycling of loosely chelated iron causes oxidative stress and lipid peroxidation that 
contribute to its cytotoxicity (23). The lipophilic iron chelator 8-hydroxyquinoline (8HQ) 
was used with FAC to induce rapid iron entry (within minutes) and acute iron overload in 
T51B cells. Fig. 2 illustrates the protective effects of purified curcuminoids and a 
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standardized turmeric extract on iron-induced lipid peroxidation in T51B cells. By this 
measure, both preparations were similarly effective, with apparent IC50s near 2 μM total 
curcuminoids and complete inhibition evident at 50 μM.
Table 1 summarizes the curcuminoid composition of the curcumin test products used in this 
study. Both purified curcuminoids and the turmeric extract contain 3 types of curcuminoids 
(curcumin, demethoxycurcumin, and bisdemethoxycurcumin). Compared to the purified 
curcuminoids, the turmeric extracts contained a slightly higher proportion of 
bisdemethoxycurcumin and correspondingly less curcumin, as well as additional compounds 
co-extracted with the curcuminoids. All 3 curcuminoids contain the keto-enol functional 
group thought to be critical for iron chelation, and all are thought to possess similar 
antioxidant and biological activities (24). Although the complete chemical profile of the 
turmeric extract remains to be determined, curcuminoids are the only turmeric components 
for which ironbinding activity has been reported.
As shown in Fig. 3, purified curcuminoids and the turmeric extract protected T51B cells 
against the cytotoxic effects of acute iron overload. The potencies of the two preparations 
were similar in this assay; both displayed minimal effective concentrations near 20 μM total 
curcuminoids. The apparent IC50s were higher than those required for inhibition of iron-
induced lipid peroxidation (Fig. 2), possibly reflecting the degradation of curcuminoids in 
cell culture over the longer experimental period (2 days for cell viability vs. 2 h for lipid 
peroxidation).
Curcuminoids protect against cytotoxicity and tumor promotion associated with chronic 
iron overload
Fig. 4 shows the curcuminoid concentration dependence for preventing growth inhibition 
caused by 500-μM FAC. This model of chronic iron overload (5 days) depends on 
physiological iron uptake to overload the cells. Maximal effects of both purified 
curcuminoids and the standardized turmeric extract were seen at curcuminoid concentrations 
between 5 and 20 μM, well below the added concentration of 500 μM iron. Turmeric was 
slightly more effective at the lowest concentration (2 μM) and more toxic at the highest 
concentration (50 μM). These data placed an upper limit on the concentrations that could be 
tested in long-term cell culture studies. Acceptable growth inhibition of 20% or less was 
observed at upper curcuminoid concentration limits for purified curcuminoids of 50 μM and 
for the standardized turmeric extract of 20 μM.
Iron was shown previously to act as a tumor promoter in T51B cells (11). Neoplastic 
transformation, as judged by colony formation in soft agar, required an initiating low dose of 
the carcinogen MNNG followed by prolonged culture in the presence of iron (given as 
FAC). To investigate effects of curcuminoids on iron-related neoplastic cell transformation, 
purified curcuminoids or turmeric extracts were given with FAC throughout the 16-wk tumor 
promotion phase (Supplemental Table 1). Three experiments were conducted using a range 
of repeated dosing conditions (Supplemental Table 2). As shown in Table 2, curcuminoids 
had two contrasting dose-dependent effects on iron-treated T51B cells. Low concentrations 
appeared to increase colony formation in soft agar. For purified curcuminoids given with 200 
μM iron, 5–10 μM curcuminoids resulted in a 3-fold increase in soft agar growth compared 
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to iron alone (P < 0.01). Similarly, for the turmeric extract, 5 μM curcuminoids appeared to 
potentiate the tumor-promoting effects of iron (although this trend was not significant).
In contrast, higher concentrations of curcuminoids blocked neoplastic transformation. At 20 
μM curcuminoids or higher, either purified curcuminoids or the standardized turmeric 
extract inhibited the tumor-promoting effect of 200 μM iron (Table 2). At 10 μM, the 
turmeric extract also appeared to inhibit tumor promotion by iron (although statistical 
significance was not achieved). Fig. 5 illustrates the compiled results for curcuminoid 
concentrations ≥20 μM for either purified curcuminoids (20–50 μM) or the standardized 
turmeric extract (20–30 μM). Both preparations decreased tumor promotion by iron to near 
background levels at the 16-wk time point (P < 0.01). Analysis of the duration of this effect 
in a single experiment suggested that the prevention by 20 μM could be maintained through 
at least 20 wk of iron exposure (Fig. 6).
These data indicate increased potency of the turmeric extracts compared to the purified 
curcuminoids, presumably due to additional noncurcuminoid compounds in turmeric. These 
compounds may independently inhibit tumor promotion, or they may alter curcuminoid 
uptake and/or degradation. As shown in Fig. 7, cells treated with 20 μM turmeric extract 
contained nearly twice the curcuminoid levels 4 h later as cells treated with 20 μM purified 
curcuminoids. Curcuminoids recovered from the cells after 1 h had essentially the same 
ratios of curcumin: demethoxycurcumin: bisdemethoxycurcumin as the starting 
preparations. For purified curcuminoids recovered from cells, the ratio was 75:22:3 (vs. 
75:22:3 in the starting material, Table 1) and for turmeric, it was 53:28:19 (vs. 58:24:18 in 
the starting material, Table 1). Evaluation of the kinetic data shown in Fig. 7 using a one-
phase decay model gave an apparent half-life in T51B cell culture for the turmeric extract 
curcuminoids of 43 h compared to 15 h for purified curcuminoids.
Discussion
Curcuminoids as cancer prevention agents in iron overload
The incidence of primary liver cancer in humans with severe iron overload is nearly 10% 
(8,9), higher than any other known risk factor. Identifying non-invasive preventive therapies 
is hampered by the long latency period (up to 30 yr in humans) and paucity of cell and 
animal models. T51B rat liver epithelial cells are a non-neoplastic cell line used previously 
to document the tumor-promoting properties of iron (11). A single subcarcinogenic initiating 
dose of MNNG followed by an extended culture in 200 μM FAC resulted in neoplastic 
transformation of the cells. FAC was chosen as the form of iron because iron citrate is found 
in the serum of hereditary hemochromatosis patients (22). Thus, this in vitro model depends 
on a physiologically relevant form of iron to progress to a physiologically relevant end point 
(growth in soft agar), making it uniquely useful for investigating preventive therapies. The 
present paper shows that 20 μM curcuminoids can block tumor-promoting effects of iron in 
T51B liver cells (Fig. 5). The specific concentration is significant in that it is insufficient to 
completely chelate the iron used in the experiment, given a binding stoichiometry of 1 or 
more curcumin molecules per iron atom (13,14). Toxic effects of iron were similarly 
inhibited by substoichiometric concentrations of curcuminoids [Figs. 2–4 and (15)]. 
Curcumin acts differently than the iron-specific chelator deferoxamine, which was required 
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in stoichiometric amounts to prevent toxicity (15) and in vitro tumor promotion by iron (11). 
Thus, block of tumor promotion is not linked to chelation, but instead appears dependent on 
curcumin entry into cells and subsequent inhibition of one or more events downstream of 
iron.
By definition, tumor promoters favor the selective growth of preneoplastic cells. This may 
occur if iron directly stimulated proliferation of those cells, as might be expected, if low iron 
levels were limiting growth. This is likely not relevant in vitro for FAC, since transferrin-
bound iron from the serum/media is readily available, and nontransferrin-bound iron does 
not stimulate cell proliferation (11,25,26). Another possibility is that free or loosely chelated 
iron is toxic to normal cells but not the transformed cells. The idea that neoplastic cells 
become resistant to effects of a growth inhibitor was proposed by Farber and colleagues as 
the “resistant hepatocyte model” of tumor promotion (27). FAC can be toxic, but we have 
not been able to detect an iron-resistant phenotype in T51B daughter cells isolated from soft 
agar, and for that reason, we do not believe that the transformed cells have acquired 
resistance. A third possibility is the related concept of compensatory proliferation, thought 
to be particularly relevant in the liver (12,28). According to this theory, cytotoxicity speeds 
the carcinogenesis process because otherwise quiescent preneoplastic cells are triggered to 
proliferate, thereby accumulating the multiple mutations required for carcinogenesis. 
Compensatory proliferation in the context of cytotoxic free iron seems most consistent with 
effects of iron in the T51B cell carcinogenesis model (11). We propose that curcuminoids 
reduce iron toxicity and/or compensatory proliferation in vitro, accounting for the observed 
block of the tumor-promoting effects of iron. This occurred at curcuminoid concentrations 
that are high enough to reduce iron toxicity but below the threshold where the curcuminoids 
themselves become toxic through some other mechanism.
Other compounds in turmeric improve curcuminoid delivery in cell culture experiments
The standardized turmeric extract appeared more effective at blocking tumor promotion by 
iron than the purified curcuminoids (Fig. 5 and Table 2). This is likely not the result of 
differences in curcuminoid composition between the turmeric extract and the purified 
preparation (i.e., a 5–6 fold higher content of bisdemethoxycurcumin in turmeric) (Table 1). 
There are no clear differences in biological activities between the three curcuminoids (for 
example, all contain the keto-enol structure important for iron binding), and we did not 
detect differences in uptake between them. More likely, other constituents in the turmeric 
extract account for the observed increase in potency. Such constituents could act 
independently of the curcuminoids, or they could increase the intracellular concentration of 
curcuminoids by facilitating/extending uptake or preventing degradation. The kinetic data in 
Fig. 7 argue for improved delivery of curcuminoids to cells in culture. The roughly twofold 
increase in potency was similar to the enhanced cellular uptake and prolonged half-life of 
curcuminoids given as the turmeric extract. How this occurs is unknown; further work is 
required to identify the molecules and characterize their interactions with curcuminoids in 
vitro and in vivo.
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Chelation by curcuminoids may increase the tumor-promoting effects of iron
Concentrations of curcuminoids below that required to block tumor promotion by iron had 
the surprising effect of increasing neoplastic transformation in the presence of iron (Table 2). 
It seems likely that this occurs only in the setting of iron overload, since many studies done 
in the absence of added iron have failed to observe carcinogenic and/or tumor-promoting 
effects of curcuminoids. There are reports that the carcinogenic effect of free iron is 
increased by lipophilic iron chelators like nitrilotriacetate (NTA) (29–32). Curcumin may act 
similarly to NTA as a membrane-permeating agent, thereby increasing the mutagenic (9) or 
tumor-promoting activities of iron. However, purified curcuminoids and turmeric extracts 
inhibited iron toxicity in short-term experiments that depended on 8HQ for rapid iron entry 
to the cells (Figs. 2 and 3). Furthermore, a significant increase in iron levels in curcumin-
treated cells was not detected (15), and curcumin does not alter liver iron levels in mice, 
although important regulators of iron homeostasis including ferritin are dysregulated 
(33,34). These points argue that transmembrane iron permeating activity of curcuminoids, if 
it exists, is significantly less than seen with 8HQ or NTA. However, even if curcuminoids do 
not transport iron across membranes, their demonstrated ability to bind iron with micromolar 
affinity is predicted to increase the solubility of ferric iron, by analogy to citrate and other 
physiological iron chelators. An increase in redox-active free iron may result, especially 
under cell culture or disease conditions in which options for iron sequestration in transferrin 
or ferritin are limited. Thus, although iron chelation does not explain inhibition of tumor 
promotion by curcuminoids, it may contribute to the increased tumor promotion activity of 
iron observed here.
We observed under very specific cell culture conditions that 20 μM curcuminoids was the 
threshold concentration for inhibition of tumor promotion in T51B cells. If a comparable 
effect occurs in vivo, a similar concentration should be required. However, this concentration 
is greater than that has been observed in the blood of animals or humans given curcuminoids 
in the diet (35). Unless bioavailability can be improved, it seems unlikely that curcuminoids 
given orally would confer this benefit to humans. Minimally, the curcumin would have to be 
injected, a daunting requirement for long-term prevention therapy. Importantly, lower 
concentrations of curcuminoids (that we found to increase in vitro tumor promotion by iron) 
approach serum levels of curcuminoids and iron-binding curcuminoid metabolites 
achievable from dietary curcumin (36). This previously unrecognized and potentially 
harmful outcome may negate any potential health benefits of curcumin or turmeric when 
iron levels are high. Further investigation of the risk/benefit of curcumin and turmeric in the 
context of elevated body iron, as exists in humans with hemochromatosis and other iron 
overload disorders, is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Structures of curcumin and related curcuminoids.
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Figure 2. 
Curcuminoids prevent iron-induced lipid peroxidation. Confluent T51B cells were treated 
for 2 h ± 200 μM iron and ±10 μM 8-hydroxyquinoline (8HQ) as indicated. Curcuminoids 
were added with iron/8HQ as either purified curcuminoids (curc at 2, 10, or 50 μM) or a 
standardized turmeric extract (turm at 2, 10, or 50 μM). Cell lysates were analyzed by 
TBARS assay and results expressed in MDA equivalents. Means ± SE from 4 replicate 
experiments are presented. (***P < 0.001 vs. iron + 8HQ reference (ref.); **P < 0.01; *P < 
0.05.)
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Figure 3. 
Curcuminoids reduce acute iron cytotoxicity. Subconfluent, proliferating T51B cells were 
treated for 2 days ± 200 μM iron and ± 10 μM 8-hydroxyquinoline (8HQ) as indicated. 
Curcuminoids were added with iron/8HQ as either purified curcuminoids (curc at 5, 10, 20, 
or 50 μM) or a standardized turmeric extract (turm at 5, 10, 20, or 50 μM). Cell number and 
viability were determined by MTT assay. Means ± SE from 3 replicate experiments are 
presented. (***P < 0.001 vs. iron + 8HQ reference (ref.); **P < 0.01; *P < 0.05.)
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Figure 4. 
Curcuminoids reduce the cytotoxicity of chronic iron loading. Proliferating T51B cells were 
treated for 5 days ± 500 μM iron. Curcuminoids were added with iron as either purified 
curcuminoids (curc at 2, 5, 10, 20, or 50 μM) or a standardized turmeric extract (turm at 2, 5, 
10, 20, or 50 μM). Cell number and viability were determined by MTT assay. Means ± SE 
from 3 replicates are presented. (**P < 0.01 vs. 500 μM iron only reference (ref.); *P < 
0.05.)
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Figure 5. 
Curcuminoids inhibit tumor promotion by iron. Proliferating T51B cells were treated with 
0.5 μg/ml MNNG for 24 h (initiated) and cultured for 16 wk with 200 μM iron and 
±curcuminoids or turmeric (≥20 μM) as described under “Methods” section. Control cells 
(no MNNG or iron) were run in parallel. Colony formation in soft agar was measured and 
results compiled from three independent experiments. The total number of soft agar dishes 
and treatment conditions were as follows: Control (n = 24 total); MNNG + iron (n = 75 
total); purified curcuminoids (curcumin; n = 60 total: 16 at 20 μM, 16 at 30 μM, and 28 at 50 
μM); and turmeric (n = 32 total: 16 at 20 μM and 16 at 30 μM). (***P < 0.001 vs. MNNG + 
iron; **P < 0.01; *P < 0.05.)
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Figure 6. 
Inhibition of tumor promotion by curcuminoids through 20 wk. Proliferating T51B cells 
were initiated with MNNG and cultured with 200 μM iron and ±20 μM curcuminoids or 
turmeric with media renewal every 2.6 days on average. Colony formation in soft agar was 
assessed at 16, 18, and 20 wk. The number of soft agar dishes in this experiment was: 
Control (n = 8 each at weeks 16–20); MNNG + iron (n = 40 each at weeks 16–20); 20 μM 
purified curcuminoids (curcumin; n = 8 each at weeks 16–20); 20 μM turmeric (n = 8 each at 
weeks 16–20).
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Figure 7. 
The in vitro pharmacokinetic properties of purified curcuminoids differ from those of the 
turmeric extract. Confluent T51B cells were treated at time zero with 200 μM iron and 20 
μM curcuminoids, given either as purified curcuminoids (circles) or standardized turmeric 
extract (squares). Curcuminoid levels in the cells at the indicated times were determined by 
absorbance at 425 nm as described under “Methods” section. The data represent means and 
SE from n = 6 independent experiments, each set with a best fit line drawn using a one-
phase decay model.
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Table 1
Relative curcuminoid composition of study test products (% of total).
Purified curcuminoids (%) Turmeric 1 (%) Turmeric 2 (%)
Curcumin 75.0 62.4 58.4
Demethoxycurcumin 21.7 21.3 23.6
Bisdemethoxycurcumin     3.35 16.3 18.0
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Table 2
Inhibition of tumor promotion by iron in vitro (16 weeks): dependence on curcuminoid concentrations 
(average number of soft agar colonies/25,000 cells).
Treatment # Colonies ± SE (n) P-value
Control   2.5 ± 0.5 (24) <0.001
MNNG + 200-μM iron# 44.3 ± 9.3 (84) Reference
+5-μM curcuminoids 27.5 ± 5.6 (8)     ns
+10-μM curcuminoids  247 ± 63 (16) <0.01
+20-μM curcuminoids 17.4 ± 5.2 (16) <0.05
+30-μM curcuminoids   1.7 ± 0.2 (16) <0.001
+50-μM curcuminoids   8.1 ± 2.1 (28) <0.001
+5-μM turmeric  162 ± 70 (16)     ns
+10-μM turmeric 29.1 ± 8.8 (16)     ns
+20-μM turmeric   0.2 ± 0.1 (16) <0.001
+30-μM turmeric   2.8 ± 1.3 (16) <0.001
#
MNNG (N-methyl-N′-nitro-N-nitrosoguanidine; FAC (ferric ammonium citrate).
n = total number of soft agar assay dishes; SE = standard error; ns = not significant.
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